Everest Medicines, AbCellera ink multiyear deal

By The Science Advisory Board staff writers

September 23, 2021 -- Everest Medicines and AbCellera have entered into a multiyear collaboration and license agreement to discover therapeutic antibodies for up to 10 targets that will be selected by Everest. The initial programs will focus on targets in oncology, Everest said.

Under the agreement, Everest will leverage AbCellera's technology, including sourcing fully humanized antibodies from the Trianni mouse, sourcing single-domain antibodies from camelids, and combining antibodies to create native bispecifics using the OrthoMab protein engineering platform.

AbCellera acquires TetraGenetics
Artificial intelligence-powered biotech and drug discovery platform AbCellera has acquired biotechnology firm TetraGenetics.
Tachyon, AbCellera to develop novel cancer antibody therapeutic
Tachyon Therapeutics and antibody discovery company AbCellera are teaming up to develop a first-in-class therapeutic antibody targeting the secreted extracellular...
AbCellera acquires Trianni for $90M
Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's...
Overlooked benefits of using polyclonal antibodies
The benefits of polyclonal antibodies as tools for assay-specific target discovery and detection are numerous. As the future of basic research, diagnostics...

Copyright © 2021 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter